Aratana Therapeutics Inc. (NASDAQ:PETX) shares fell 4.9% during trading on Wednesday . The company traded as low as $8.62 and last traded at $8.78, with a volume of 429,108 shares traded. The stock had previously closed at $9.23.

A number of brokerages recently commented on PETX. Barclays PLC decreased their price target on Aratana Therapeutics from $15.00 to $11.00 and set an “overweight” rating on the stock in a research report on Thursday, August 11th. Credit Suisse Group AG restated a “buy” rating and issued a $11.00 price target on shares of Aratana Therapeutics in a research report on Wednesday, August 10th. Jefferies Group started coverage on Aratana Therapeutics in a research report on Friday, August 19th. They issued a “buy” rating and a $13.00 target price on the stock. William Blair reiterated an “outperform” rating on shares of Aratana Therapeutics in a research report on Wednesday, August 17th. Finally, Zacks Investment Research cut Aratana Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, July 13th. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $11.28.

The firm has a 50 day moving average of $8.06 and a 200-day moving average of $6.33. The stock’s market cap is $314.13 million.

Aratana Therapeutics (NASDAQ:PETX) last issued its earnings results on Thursday, August 4th. The biopharmaceutical company reported $0.61 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.24 by $0.37. During the same quarter last year, the business earned ($0.23) EPS. The firm earned $38.05 million during the quarter, compared to analysts’ expectations of $15.14 million. On average, equities analysts anticipate that Aratana Therapeutics Inc. will post ($0.73) EPS for the current year.

In related news, insider Julia A. Stephanus sold 30,000 shares of the firm’s stock in a transaction on Tuesday, June 28th. The stock was sold at an average price of $6.25, for a total value of $187,500.00. Following the completion of the transaction, the insider now owns 127,503 shares in the company, valued at approximately $796,893.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Peter Steven St sold 50,000 shares of the firm’s stock in a transaction on Tuesday, August 9th. The stock was sold at an average price of $9.25, for a total value of $462,500.00. Following the completion of the transaction, the insider now owns 642,793 shares of the company’s stock, valued at approximately $5,945,835.25. The disclosure for this sale can be found here.

Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.